Jefferies Downgrades Replimune Group (REPL) After FDA Decision Creates Uncertainty
Jefferies has downgraded Replimune Group, Inc. (REPL) from Buy to Hold and lowered its price target to $2 from $13 due to increased uncertainty following the FDA’s complete response letter regarding RP1. The firm noted that the setback limits near-term visibility and makes the company’s development trajectory less clear, depending on regulatory outcomes.
Tickers: $REPL
Topics: Biotech FDA Investment Outlook Regulatory Approval Replimune Group RP1